We are excited to be a part of this journey!
We are thrilled to announce the launch of KOMO BIOSCIENCES! KOMO BIOSCIENCES is a next-generation precision genome engineering technology company driven by the power of highly-evolved and highly-efficient hyperactive integrases. Our pipeline of highly-evolved integrases can stably incorporate large pieces of DNA into a pre-defined, high-expressing region in the human genome at up to 80% integration efficiency per chromosome in up to 96% of cells. This efficient, rapid, flexible precision genome engineering tool is non-viral, non-nuclease, and does not induce unprotected double-strand DNA breaks. KOMO BIOSCIENCES’ precision genome engineering platform, KOMO FT®(Fast Track) including proprietary cell lines and high-efficiency integrases can address limitations of current genome engineering methods (CRISPR and its derivatives) with respect to off-target editing, low efficiency, and inability to insert large fragments of DNA. Additionally, our technology platform can accelerate development and manufacturing of biologics and advanced therapies by reducing cell line development from several months to just weeks, thus reducing manufacturing timelines to clinic. KOMO BIOSCIENCES aims to accelerate the efforts of therapeutic developers, contract research and development manufacturing organizations, and government agencies through licensing agreements and strategic partnerships. Thank you Ryan Cross and Endpoints News for the exclusive coverage. #breakingnews #endpoints #startup #integrases #launch #genomeengineering #geneediting #accelerate #development #manufacturing #celllinedevelopment #biologics #antibodies #advancedtherapies #cellandgenetherapy #viralvectors University of Hawaii at Manoa Jesse B. Owens Genesis BioCapital Jennifer Manning Ray Tabibiazar Omid Harandi Jay Wohlgemuth MD Daniel Chen, M.D. Ph.D. https://lnkd.in/eRtC6rkq